Intranasal COVID-19 Vaccine Developed by Indian Immunologicals and Griffith University

Share:    

Aug 27, 2024 17:10

Indian Immunologicals Ltd and Griffith University have jointly developed a live-attenuated intranasal booster vaccine for COVID-19, aiming to enhance vaccination rates and combat the ongoing pandemic.
Intranasal COVID-19 Vaccine Developed by Indian Immunologicals and Griffith University
New Delhi, Aug 27 (PTI) Indian Immunologicals Ltd on Tuesday said it has jointly developed an intranasal vaccine for COVID-19.

The company said it has come up with a live-attenuated needle-free intra-nasal booster vaccine developed against SARS-CoV-2 using codon deoptimisation technology in collaboration with Griffith University, Australia.


"This accomplishment signifies a major step forward in our battle against COVID-19. The development of this vaccine not only highlights our dedication to innovation in public health but also demonstrates the company's capability in adopting novel technology," Indian Immunologicals Ltd (IIL) MD K Anand Kumar said in a statement.

By facilitating non-invasive immunisation, IIL aims to enhance vaccination rates, ultimately safeguarding more individuals and communities, he added.

As per the Hyderabad-based firm, COVID-19 is still a cause of around 1,700 deaths a week around the world.
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume
  • Biocon
  • 437.30 (+ 6.52)
  • 48029042

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback